| Chia-wai David Chang, MD | |
|
812 N Keene St, Columbia, MO 65201-6633 | |
| (573) 817-3000 | |
| (573) 876-6950 |
| Full Name | Chia-wai David Chang |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 25 Years |
| Location | 812 N Keene St, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013975986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0007X | Otolaryngology - Plastic Surgery Within The Head & Neck | 2005023723 (Missouri) | Secondary |
| 207Y00000X | Otolaryngology | 2005023723 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Missouri Health Care | Columbia, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
News Archive
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.
FoodMinds, a food and nutrition company that harnesses science, public affairs and communications, is rolling into 2010 with new client partnerships and an expanding roster of full-time team members.
Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.
Researchers at the Perelman School of Medicine at the University of Pennsylvania in collaboration with the Roswell Park Cancer Institute have received an $8 million grant from the National Cancer Institute to study the effects of photodynamic light therapy (PDT) in patients with malignant pleural mesothelioma, a rare, aggressive and deadly cancer that most often manifests itself in the lining of the lungs and is caused almost exclusively by exposure to asbestos.
› Verified 8 days ago
| Entity Name | Capital Region Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477980837 PECOS PAC ID: 4688573686 Enrollment ID: O20070323000507 |
News Archive
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.
FoodMinds, a food and nutrition company that harnesses science, public affairs and communications, is rolling into 2010 with new client partnerships and an expanding roster of full-time team members.
Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.
Researchers at the Perelman School of Medicine at the University of Pennsylvania in collaboration with the Roswell Park Cancer Institute have received an $8 million grant from the National Cancer Institute to study the effects of photodynamic light therapy (PDT) in patients with malignant pleural mesothelioma, a rare, aggressive and deadly cancer that most often manifests itself in the lining of the lungs and is caused almost exclusively by exposure to asbestos.
› Verified 8 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.
FoodMinds, a food and nutrition company that harnesses science, public affairs and communications, is rolling into 2010 with new client partnerships and an expanding roster of full-time team members.
Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.
Researchers at the Perelman School of Medicine at the University of Pennsylvania in collaboration with the Roswell Park Cancer Institute have received an $8 million grant from the National Cancer Institute to study the effects of photodynamic light therapy (PDT) in patients with malignant pleural mesothelioma, a rare, aggressive and deadly cancer that most often manifests itself in the lining of the lungs and is caused almost exclusively by exposure to asbestos.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chia-wai David Chang, MD Po Box 7687, Columbia, MO 65205-7687 Ph: (573) 817-3000 | Chia-wai David Chang, MD 812 N Keene St, Columbia, MO 65201-6633 Ph: (573) 817-3000 |
News Archive
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.
FoodMinds, a food and nutrition company that harnesses science, public affairs and communications, is rolling into 2010 with new client partnerships and an expanding roster of full-time team members.
Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.
Researchers at the Perelman School of Medicine at the University of Pennsylvania in collaboration with the Roswell Park Cancer Institute have received an $8 million grant from the National Cancer Institute to study the effects of photodynamic light therapy (PDT) in patients with malignant pleural mesothelioma, a rare, aggressive and deadly cancer that most often manifests itself in the lining of the lungs and is caused almost exclusively by exposure to asbestos.
› Verified 8 days ago
Andrea Lee Hanick, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1000 W Nifong Blvd Ste 100, Columbia, MO 65203 Phone: 573-214-2000 | |
Dr. David C. Mechlin, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 303 N Keene St, Suite 401, Columbia, MO 65201 Phone: 573-884-2200 Fax: 573-884-8836 | |
Tiffany Patterson Baugh, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr # Ma314, Columbia, MO 65212 Phone: 573-882-6737 Fax: 573-884-4205 | |
Juan Carlos Yanez-siller, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr # Ma314, Columbia, MO 65212 Phone: 573-882-6737 Fax: 573-884-4205 | |
Dr. James S. Denninghoff, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1701 E Broadway, Suite 304, Columbia, MO 65201 Phone: 573-815-0662 Fax: 573-443-1162 | |
Megan Gillespie, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1 Hospital Drive, Ma314 / Dc027.00, Columbia, MO 65212 Phone: 573-882-7935 Fax: 573-884-4205 |